ArticleScientific reports2026
Prognostic role of smoking in metastatic renal cell carcinoma in real-world data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC).
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Smoking has been implicated as a potential factor influencing cancer progression and outcomes in various malignancies, including metastatic renal cell carcinoma (mRCC). This study aimed to evaluate the effect of smoking status on treatment outcomes in mRCC patients, with a focus on metastatic sites. This retrospective cohort study utilized data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC). The primary endpoint of the study was overall survival (OS) across metastatic sites. A total of 779 patients were included, of whom 464 (58.1%) were former/current smokers. Smoking status did not significantly affect OS in the overall cohort. However, in the bone metastatic subgroup, former/current smokers exhibited worse OS compared to never smokers (33.9 vs. 22.1 months; p = 0.005). Multivariate Cox regression analysis showed that former/current smoking was an independent predictor for OS in patients with bone metastasis (former/current smoker vs never smoker HR 1.44, 95% CI 1.05–1.99; p = 0.026) and bone-only metastasis (former/current smoker vs never smoker HR 4.44; 95% CI 1.27–15.55; p = 0.020) after adjusting for confounding factors. Smoking is an independent predictor of poor survival in mRCC patients with bone metastases, highlighting the organ-specific effects of smoking on cancer progression. Further research is needed to explore underlying mechanisms and evaluate outcomes in the context of modern therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.